blog
Read our insights on what’s happening in the industry today.
Cultural Competence in Research Rooted in Humility and Respect
Achieving cultural competency is increasingly important in our global community, especially to reach the populations who would most benefit from research. In this blog post, we discuss this importance as well as examples of successful community engagement.
New Horizons for TB Vaccine Research Involve Early Awareness, Coordinated Efforts and Equitable Access: Thoughts from the 6th Annual Global Forum on TB Vaccines
Several FHI Clinical team members attended the 6th Annual Global Forum on TB Vaccines. Based on their conversations and session attendance, they provide their thoughts on the future of tuberculosis prevention and vaccine development.
Personal Choice in Research: Respecting Reasons for Participation and Nonparticipation
As researchers, we rely on the willingness of people to participate in our studies, and participant recruitment and retention continue to be one of the biggest challenges. There are numerous reasons for this, some that we can address and others that we might just have to accept.
FHI Clinical Executive Team Members Visit the PREVAIL Network in Liberia
In the fall of 2021, a small team from FHI Clinical headed to Liberia to meet the FHI Clinical PREVAIL network team. Upon their return from visiting Liberia and each of the network sites, we asked the team some questions about the trip and their accomplishments.
Rapid Evaluation of Treatments for COVID-19: Adaptive COVID-19 Treatment Trial (ACTT)
The FHI Clinical team is thrilled to support the development of multiple COVID-19 therapies that offer patients safe, effective treatment options during the ongoing pandemic and beyond.
Webinar Wrap-Up: Are CROs prepared for ICH E6 (R3)?
Making sure CROs are prepared for the next iteration of ICH regulations was the topic of a recent webinar sponsored by Oracle. The expert panel featured FHI Clinical’s own Rob King, Chief Operating Officer, alongside executives from other organizations.
Supporting Evidence-Based Decisions About Pneumococcal Conjugate Vaccines
Results of recent studies that we supported focusing on vaccination against Streptococcus pneumoniae, a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia, were recently published, providing more evidence for health departments to use when developing their pediatric vaccination strategies.
Roundtable Wrap-Up: The Impact of TB Preventive Treatment on Vaccine Development
Expert panelists from the FHI Clinical roundtable at the Virtual Global Forum on TB Vaccines conference shared their thoughts on the new WHO guidelines for TPT and the implications for TB vaccine development. See what they had to say here.
